Editas Medicine (EDIT) Shares Outstanding (2015 - 2025)

Editas Medicine (EDIT) has reported Shares Outstanding (Entity) for 11 consecutive years, with $97.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Shares Outstanding (Entity) rose 18.29% year-over-year to $97.9 million; the TTM figure through Dec 2025 stood at $97.9 million (up 18.29% YoY), while the FY2025 annual figure was $97.9 million, up 18.29% from the prior year.
• Shares Outstanding (Entity) grew to $97.9 million in Q4 2025 per EDIT's latest filing, from $93.3 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $97.9 million in Q4 2025 and bottomed at $67.5 million in Q1 2021.
• Historically, Shares Outstanding (Entity) has averaged $77.7 million across 5 years, with a median of $81.6 million in 2023.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) gained 23.12% — and 2023, when it advanced 0.57%.
• Editas Medicine's Shares Outstanding (Entity) stood at $68.4 million in 2021, then advanced by 0.6% to $68.8 million in 2022, then increased by 18.77% to $81.8 million in 2023, then climbed by 1.18% to $82.7 million in 2024, then advanced by 18.29% to $97.9 million in 2025.
• Business Quant data shows EDIT's Shares Outstanding (Entity) at $97.9 million in Q4 2025, $93.3 million in Q3 2025, and $87.4 million in Q2 2025.